CL2023003694A1 - Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso - Google Patents

Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso

Info

Publication number
CL2023003694A1
CL2023003694A1 CL2023003694A CL2023003694A CL2023003694A1 CL 2023003694 A1 CL2023003694 A1 CL 2023003694A1 CL 2023003694 A CL2023003694 A CL 2023003694A CL 2023003694 A CL2023003694 A CL 2023003694A CL 2023003694 A1 CL2023003694 A1 CL 2023003694A1
Authority
CL
Chile
Prior art keywords
pcrv
antibodies
bind
methods
compositions
Prior art date
Application number
CL2023003694A
Other languages
English (en)
Inventor
Kyratsous Christos
Coppi Alida
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2023003694A1 publication Critical patent/CL2023003694A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona anticuerpos y fragmentos de unión al antígeno de anticuerpos que se unen a PcrV de Pseudomonas aeruginosa, y métodos para usarlos. De acuerdo con determinadas modalidades, la descripción incluye anticuerpos y fragmentos de unión al antígeno de anticuerpos que se unen a PcrV. Los anticuerpos anti-PcrV y fragmentos de unión al antígeno son útiles para la prevención y el tratamiento de infecciones por P. aeruginosa.
CL2023003694A 2019-06-11 2023-12-11 Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso CL2023003694A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962860146P 2019-06-11 2019-06-11

Publications (1)

Publication Number Publication Date
CL2023003694A1 true CL2023003694A1 (es) 2024-06-14

Family

ID=71948699

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2021003215A CL2021003215A1 (es) 2019-06-11 2021-12-03 Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos
CL2023003695A CL2023003695A1 (es) 2019-06-11 2023-12-11 Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
CL2023003694A CL2023003694A1 (es) 2019-06-11 2023-12-11 Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
CL2023003696A CL2023003696A1 (es) 2019-06-11 2023-12-11 Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2021003215A CL2021003215A1 (es) 2019-06-11 2021-12-03 Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos
CL2023003695A CL2023003695A1 (es) 2019-06-11 2023-12-11 Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023003696A CL2023003696A1 (es) 2019-06-11 2023-12-11 Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso

Country Status (17)

Country Link
US (2) US11655286B2 (es)
EP (1) EP3983015A1 (es)
JP (1) JP2022536469A (es)
KR (1) KR20220019755A (es)
CN (1) CN113966343A (es)
AU (1) AU2020292283A1 (es)
BR (1) BR112021023335A2 (es)
CA (1) CA3140075A1 (es)
CL (4) CL2021003215A1 (es)
CO (1) CO2021015254A2 (es)
EA (1) EA202192810A1 (es)
IL (1) IL288727A (es)
MA (2) MA56205A (es)
MX (1) MX2021015156A (es)
PH (1) PH12021552903A1 (es)
SG (1) SG11202112462RA (es)
WO (1) WO2020252029A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10597439B2 (en) 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
CN114404614B (zh) * 2022-01-28 2024-04-23 上海交通大学 一种靶向铜绿假单胞菌的免疫脂质体及其制备方法和应用
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
WO2024206669A2 (en) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Antibodies for targeting cd47 and b7h3 and methods of use thereof
EP4735478A1 (en) 2023-06-28 2026-05-06 Universität zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa
CN118530352B (zh) * 2024-05-11 2025-03-25 重庆原伦生物科技有限公司 一种特异性识别铜绿假单胞菌PcrV的抗体及其应用
CN118440191B (zh) * 2024-05-11 2025-06-10 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1353688B1 (en) 2001-01-26 2006-12-06 MCW Research Foundation, Inc. Method and compositions for immunization with the pseudomonas v antigen
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
SG186017A1 (en) * 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
AU2009203426C1 (en) 2008-01-10 2012-05-31 Shionogi & Co., Ltd. Antibody directed against PcrV
EA017288B1 (ru) 2008-01-11 2012-11-30 Эли Лилли Энд Компани (E)-N-{3-[1-(8-ФТОР-11Н-10-ОКСА-1-АЗАДИБЕНЗО[a,d]ЦИКЛОГЕПТЕН-5-ИЛИДЕН)ПРОПИЛ]ФЕНИЛ}МЕТАНСУЛЬФОНАМИД В КАЧЕСТВЕ МОДУЛЯТОРА РЕЦЕПТОРОВ ГЛЮКОКОРТИКОИДОВ ДЛЯ ЛЕЧЕНИЯ РЕВМАТИЗМА
DK2407537T6 (en) 2009-03-11 2015-07-27 Shionogi & Co PcrV HUMANIZED ANTIBODY WITH ACTIVITY ANTIPSEUDOMONAL
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
WO2012122533A2 (en) 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
US10597439B2 (en) * 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
EP2793944B1 (en) 2011-12-23 2025-10-08 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
JP2015535005A (ja) * 2012-11-06 2015-12-07 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
WO2017095744A1 (en) * 2015-11-30 2017-06-08 Medimmune, Llc Method for preventing or treating nosocomial pneumonia
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
BR112020004977A2 (pt) 2017-09-29 2020-10-06 Regeneron Pharmaceuticals, Inc. moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos

Also Published As

Publication number Publication date
CA3140075A1 (en) 2020-12-17
IL288727A (en) 2022-02-01
WO2020252029A1 (en) 2020-12-17
US11655286B2 (en) 2023-05-23
CO2021015254A2 (es) 2021-11-19
CN113966343A (zh) 2022-01-21
MX2021015156A (es) 2022-01-18
EP3983015A1 (en) 2022-04-20
MA54975B1 (fr) 2023-08-31
SG11202112462RA (en) 2021-12-30
CL2023003695A1 (es) 2024-06-14
AU2020292283A1 (en) 2021-12-23
US20200392210A1 (en) 2020-12-17
CL2023003696A1 (es) 2024-06-14
KR20220019755A (ko) 2022-02-17
CL2021003215A1 (es) 2022-09-30
MA56205A (fr) 2022-04-20
PH12021552903A1 (en) 2022-04-04
EA202192810A1 (ru) 2022-03-05
US20230322907A1 (en) 2023-10-12
JP2022536469A (ja) 2022-08-17
BR112021023335A2 (pt) 2022-01-04
US12552856B2 (en) 2026-02-17
MA54975A1 (fr) 2022-05-31

Similar Documents

Publication Publication Date Title
CL2023003695A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
CL2020001391A1 (es) Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina.
CL2023001092A1 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
ECSP19086810A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2017000985A (es) Anticuerpos anti-pd-1.
MX2017001597A (es) Anticuerpos anti-pd-l1.
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2019008786A2 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo
MX2021008216A (es) Anticuerpos anti-tigit.
CL2020002449A1 (es) Anticuerpos anti-pfrh5 y fragmentos de unión de antígenos de los mismos.
UY36801A (es) PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE CONDICIONES INMUNES RELACIONADAS CON INFECCIONES UTILIZANDO UNA COMPOSICION QUE COMPRENDE IgM
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
BR112022002459A2 (pt) Processo para a preparação de 2-cloro-1-(2-clorotiazol-5-il)etanona
AR122660A2 (es) Anticuerpos anti-pmel17 y conjugados de los mismos